Download PDF
Thromb Haemost 2023; 123(10): 931-944
DOI: 10.1055/s-0043-1768969
Review Article

Pathophysiological Aspects of COVID-19-Associated Vasculopathic Diseases

Thiemo Greistorfer
1   Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
,
Philipp Jud
1   Division of Angiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Since the beginning of coronavirus disease 2019 (COVID-19) pandemic, numerous data reported potential effects on the cardiovascular system due to infection by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), which may lead to COVID-19-associated vasculopathies during the acute phase and measurable vascular changes in the convalescent phase. Infection by SARS-CoV-2 seems to have specific direct and indirect effects on the endothelium, immune and coagulation systems thus promoting endothelial dysfunction, immunothrombosis, and formation of neutrophil extracellular traps although the exact mechanisms still need to be elucidated. This review represents a recent update of pathophysiological pathways of the respective three major mechanisms contributing to COVID-19 vasculopathies and vascular changes and includes clinical implications and significance of outcome data.

Keywords

COVID-19 - endothelial dysfunction - coagulation - immune system - immunothrombosis - neutrophil extracellular traps


Publication History

Received: 20 December 2022

Accepted: 19 April 2023

Article published online:
12 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 World Health Organization. WHO-convened global study of origins of SARS-CoV-2: China part. World Health Organization; 2021. . Accessed April 28, 2023 at: https://www.who.int/publications/i/item/who-convened-global-study-of-origins-of-sars-cov-2-china-part
    Google Scholar
  • 2 World Health Organization. WHO Coronavirus (COVID-19) Dashboard. World Health Organization. 2022 29.03.2023. Accessed March 31, 2023 at: https://covid19.who.int
    PubMedGoogle Scholar
  • 3 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Giryes S, Bragazzi NL, Bridgewood C, De Marco G, McGonagle D. COVID-19 vasculitis and vasculopathy-distinct immunopathology emerging from the close juxtaposition of type II pneumocytes and pulmonary endothelial cells. Semin Immunopathol 2022; 44 (03) 375-390
    CrossrefPubMedGoogle Scholar
  • 5 Tufano A, Rendina D, Abate V. et al. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: a systematic review with meta-analysis. J Clin Med 2021; 10 (21) 4925
    CrossrefPubMedGoogle Scholar
  • 6 Birnhuber A, Fließer E, Gorkiewicz G. et al. Between inflammation and thrombosis: endothelial cells in COVID-19. Eur Respir J 2021; 58 (03) 2100377
    CrossrefPubMedGoogle Scholar
  • 7 Bonaventura A, Vecchié A, Dagna L. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021; 21 (05) 319-329
    CrossrefPubMedGoogle Scholar
  • 8 Leppkes M, Knopf J, Naschberger E. et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 2020; 58: 102925
    CrossrefPubMedGoogle Scholar
  • 9 Nicosia RF, Ligresti G, Caporarello N, Akilesh S, Ribatti D. COVID-19 vasculopathy: mounting evidence for an indirect mechanism of endothelial injury. Am J Pathol 2021; 191 (08) 1374-1384
    CrossrefPubMedGoogle Scholar
  • 10 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271.e8-280.e8
    CrossrefPubMedGoogle Scholar
  • 11 Zhang J, Tecson KM, McCullough PA. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. Rev Cardiovasc Med 2020; 21 (03) 315-319
    CrossrefPubMedGoogle Scholar
  • 12 Bayati A, Kumar R, Francis V, McPherson PS. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J Biol Chem 2021; 296: 100306
    CrossrefPubMedGoogle Scholar
  • 13 Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020; 5 (04) 562-569
    CrossrefPubMedGoogle Scholar
  • 14 Wang H, Yang P, Liu K. et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 2008; 18 (02) 290-301
    CrossrefPubMedGoogle Scholar
  • 15 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395 (10234): 1417-1418
    CrossrefPubMedGoogle Scholar
  • 16 Dittmayer C, Meinhardt J, Radbruch H. et al. Why misinterpretation of electron micrographs in SARS-CoV-2-infected tissue goes viral. Lancet 2020; 396 (10260): e64-e65
    CrossrefPubMedGoogle Scholar
  • 17 Goldsmith CS, Miller SE, Martines RB, Bullock HA, Zaki SR. Electron microscopy of SARS-CoV-2: a challenging task. Lancet 2020; 395 (10238): e99
    CrossrefPubMedGoogle Scholar
  • 18 McCracken IR, Saginc G, He L. et al. Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation 2021; 143 (08) 865-868
    CrossrefPubMedGoogle Scholar
  • 19 Schimmel L, Chew KY, Stocks CJ. et al. Endothelial cells are not productively infected by SARS-CoV-2. Clin Transl Immunology 2021; 10 (10) e1350
    CrossrefPubMedGoogle Scholar
  • 20 Satturwar S, Fowkes M, Farver C. et al. Postmortem findings associated with SARS-CoV-2: systematic review and meta-analysis. Am J Surg Pathol 2021; 45 (05) 587-603
    CrossrefPubMedGoogle Scholar
  • 21 Chen G, Wu D, Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130 (05) 2620-2629
    CrossrefPubMedGoogle Scholar
  • 22 Beaulieu LM, Lin E, Mick E. et al. Interleukin 1 receptor 1 and interleukin 1β regulate megakaryocyte maturation, platelet activation, and transcript profile during inflammation in mice and humans. Arterioscler Thromb Vasc Biol 2014; 34 (03) 552-564
    CrossrefPubMedGoogle Scholar
  • 23 Cozzolino F, Torcia M, Aldinucci D. et al. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci U S A 1990; 87 (17) 6487-6491
    CrossrefPubMedGoogle Scholar
  • 24 Wang JM, Sica A, Peri G. et al. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb 1991; 11 (05) 1166-1174
    CrossrefPubMedGoogle Scholar
  • 25 Ambrosino P, Calcaterra IL, Mosella M. et al. Endothelial dysfunction in COVID-19: a unifying mechanism and a potential therapeutic target. Biomedicines 2022; 10 (04) 812
    CrossrefPubMedGoogle Scholar
  • 26 Angelini DJ, Hyun SW, Grigoryev DN. et al. TNF-alpha increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia. Am J Physiol Lung Cell Mol Physiol 2006; 291 (06) L1232-L1245
    CrossrefPubMedGoogle Scholar
  • 27 Desai TR, Leeper NJ, Hynes KL, Gewertz BL. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res 2002; 104 (02) 118-123
    CrossrefPubMedGoogle Scholar
  • 28 Six I, Guillaume N, Jacob V. et al. The endothelium and COVID-19: an increasingly clear link brief title: endotheliopathy in COVID-19. Int J Mol Sci 2022; 23 (11) 6196
    CrossrefPubMedGoogle Scholar
  • 29 Otifi HM, Adiga BK. Endothelial dysfunction in Covid-19 infection. Am J Med Sci 2022; 363 (04) 281-287
    CrossrefPubMedGoogle Scholar
  • 30 Smadja DM, Guerin CL, Chocron R. et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis 2020; 23 (04) 611-620
    CrossrefPubMedGoogle Scholar
  • 31 Spadaro S, Fogagnolo A, Campo G. et al. Markers of endothelial and epithelial pulmonary injury in mechanically ventilated COVID-19 ICU patients. Crit Care 2021; 25 (01) 74
    CrossrefPubMedGoogle Scholar
  • 32 Akbari H, Tabrizi R, Lankarani KB. et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Life Sci 2020; 258: 118167
    CrossrefPubMedGoogle Scholar
  • 33 Chang Y, Bai M, You Q. Associations between serum interleukins (IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10) and disease severity of COVID-19: a systematic review and meta-analysis. BioMed Res Int 2022; 2022: 2755246
    CrossrefPubMedGoogle Scholar
  • 34 Hannemann J, Balfanz P, Schwedhelm E. et al. Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients. Sci Rep 2021; 11 (01) 9895
    CrossrefPubMedGoogle Scholar
  • 35 Karacaer C, Yaylaci S, Demirci T. et al. Association of mortality and endothelial dysfunction with serum ADMA level in COVID-19 patients. Pak J Med Sci 2022; 38 (07) 1808-1815
    CrossrefPubMedGoogle Scholar
  • 36 Rees CA, Rostad CA, Mantus G. et al. Altered amino acid profile in patients with SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2021; 118 (25) e2101708118
    CrossrefPubMedGoogle Scholar
  • 37 Garnier Y, Claude L, Hermand P. et al. Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner. Br J Haematol 2022; 196 (05) 1159-1169
    CrossrefPubMedGoogle Scholar
  • 38 Charfeddine S, Ibn Hadj Amor H, Jdidi J. et al. Long COVID 19 syndrome: is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med 2021; 8: 745758
    CrossrefPubMedGoogle Scholar
  • 39 Izzo R, Trimarco V, Mone P. et al. Combining L-arginine with vitamin C improves long-COVID symptoms: the LINCOLN survey. Pharmacol Res 2022; 183: 106360
    CrossrefPubMedGoogle Scholar
  • 40 Jud P, Gressenberger P, Muster V. et al. Evaluation of endothelial dysfunction and inflammatory vasculopathy after SARS-CoV-2 infection-a cross-sectional study. Front Cardiovasc Med 2021; 8: 750887
    CrossrefPubMedGoogle Scholar
  • 41 Oikonomou E, Souvaliotis N, Lampsas S. et al. Endothelial dysfunction in acute and long standing COVID-19: a prospective cohort study. Vascul Pharmacol 2022; 144: 106975
    CrossrefPubMedGoogle Scholar
  • 42 Oliveira MR, Back GD, da Luz Goulart C, Domingos BC, Arena R, Borghi-Silva A. Endothelial function provides early prognostic information in patients with COVID-19: a cohort study. Respir Med 2021; 185: 106469
    CrossrefPubMedGoogle Scholar
  • 43 Schnaubelt S, Oppenauer J, Tihanyi D. et al. Arterial stiffness in acute COVID-19 and potential associations with clinical outcome. J Intern Med 2021; 290 (02) 437-443
    CrossrefPubMedGoogle Scholar
  • 44 Cristina-Oliveira M, Meireles K, Gil S. et al. Carotid intima-media thickness and flow-mediated dilation do not predict acute in-hospital outcomes in patients hospitalized with COVID-19. Am J Physiol Heart Circ Physiol 2022; 322 (06) H906-H913
    CrossrefPubMedGoogle Scholar
  • 45 Jud P, Kessler HH, Brodmann M. Case report: changes of vascular reactivity and arterial stiffness in a patient with Covid-19 infection. Front Cardiovasc Med 2021; 8: 671669
    CrossrefPubMedGoogle Scholar
  • 46 Gao YP, Zhou W, Huang PN. et al. Persistent endothelial dysfunction in coronavirus disease-2019 survivors late after recovery. Front Med (Lausanne) 2022; 9: 809033
    CrossrefPubMedGoogle Scholar
  • 47 Ambrosino P, Calcaterra I, Molino A. et al. Persistent endothelial dysfunction in post-acute COVID-19 syndrome: a case-control study. Biomedicines 2021; 9 (08) 957
    CrossrefPubMedGoogle Scholar
  • 48 Ratchford SM, Stickford JL, Province VM. et al. Vascular alterations among young adults with SARS-CoV-2. Am J Physiol Heart Circ Physiol 2021; 320 (01) H404-H410
    CrossrefPubMedGoogle Scholar
  • 49 Riou M, Oulehri W, Momas C. et al. Reduced flow-mediated dilatation is not related to COVID-19 severity three months after hospitalization for SARS-CoV-2 infection. J Clin Med 2021; 10 (06) 1318
    CrossrefPubMedGoogle Scholar
  • 50 Lambadiari V, Mitrakou A, Kountouri A. et al. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur J Heart Fail 2021; 23 (11) 1916-1926
    CrossrefPubMedGoogle Scholar
  • 51 Szeghy RE, Province VM, Stute NL. et al. Carotid stiffness, intima-media thickness and aortic augmentation index among adults with SARS-CoV-2. Exp Physiol 2022; 107 (07) 694-707
    CrossrefPubMedGoogle Scholar
  • 52 Zanoli L, Gaudio A, Mikhailidis DP. et al; Methuselah Study Group. Vascular dysfunction of COVID-19 is partially reverted in the long-term. Circ Res 2022; 130 (09) 1276-1285
    CrossrefPubMedGoogle Scholar
  • 53 Chioh FW, Fong SW, Young BE. et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife 2021; 10: e64909
    CrossrefPubMedGoogle Scholar
  • 54 Fogarty H, Townsend L, Morrin H. et al; Irish COVID-19 Vasculopathy Study (iCVS) investigators. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost 2021; 19 (10) 2546-2553
    CrossrefPubMedGoogle Scholar
  • 55 Gianni P, Goldin M, Ngu S, Zafeiropoulos S, Geropoulos G, Giannis D. Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: a review. World J Exp Med 2022; 12 (04) 53-67
    CrossrefPubMedGoogle Scholar
  • 56 O'Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O'Donnell JS. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol 2020; 7 (08) e553-e555
    CrossrefPubMedGoogle Scholar
  • 57 Asokananthan N, Graham PT, Fink J. et al. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 2002; 168 (07) 3577-3585
    CrossrefPubMedGoogle Scholar
  • 58 Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration 2017; 93 (03) 212-225
    CrossrefPubMedGoogle Scholar
  • 59 Goswami J, MacArthur TA, Sridharan M. et al. A review of pathophysiology, clinical features, and management options of COVID-19 associated coagulopathy. Shock 2021; 55 (06) 700-716
    CrossrefPubMedGoogle Scholar
  • 60 Ruf W. New players in the sepsis-protective activated protein C pathway. J Clin Invest 2010; 120 (09) 3084-3087
    CrossrefPubMedGoogle Scholar
  • 61 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13 (01) 34-45
    CrossrefPubMedGoogle Scholar
  • 62 Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 2019; 133 (09) 906-918
    CrossrefPubMedGoogle Scholar
  • 63 Thacker VV, Sharma K, Dhar N, Mancini GF, Sordet-Dessimoz J, McKinney JD. Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model. EMBO Rep 2021; 22 (06) e52744
    CrossrefPubMedGoogle Scholar
  • 64 Cenko E, Badimon L, Bugiardini R. et al. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovasc Res 2021; 117 (14) 2705-2729
    CrossrefPubMedGoogle Scholar
  • 65 Nicolai L, Leunig A, Brambs S. et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation 2020; 142 (12) 1176-1189
    CrossrefPubMedGoogle Scholar
  • 66 Goshua G, Pine AB, Meizlish ML. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol 2020; 7 (08) e575-e582
    CrossrefPubMedGoogle Scholar
  • 67 Juneja GK, Castelo M, Yeh CH. et al; COVID-BEACONS investigators. Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. J Thromb Haemost 2021; 19 (06) 1546-1557
    CrossrefPubMedGoogle Scholar
  • 68 Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res 2020; 195: 219-225
    CrossrefPubMedGoogle Scholar
  • 69 Andrianto, Al-Farabi MJ, Nugraha RA, Marsudi BA, Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Microvasc Res 2021; 138: 104224
    CrossrefPubMedGoogle Scholar
  • 70 Doevelaar AAN, Bachmann M, Hölzer B. et al. von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit Care Med 2021; 49 (05) e512-e520
    CrossrefPubMedGoogle Scholar
  • 71 Ward SE, Fogarty H, Karampini E. et al; Irish COVID-19 Vasculopathy Study (iCVS) investigators. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 2021; 19 (08) 1914-1921
    CrossrefPubMedGoogle Scholar
  • 72 Pascreau T, Zia-Chahabi S, Zuber B, Tcherakian C, Farfour E, Vasse M. ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19. Thromb Res 2021; 204: 138-140
    CrossrefPubMedGoogle Scholar
  • 73 Fogarty H, Ward SE, Townsend L. et al; Irish COVID-19 Vasculopathy Study (iCVS) Investigators. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost 2022; 20 (10) 2429-2438
    CrossrefPubMedGoogle Scholar
  • 74 Prasannan N, Heightman M, Hillman T. et al. Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv 2022; 6 (13) 4041-4048
    CrossrefPubMedGoogle Scholar
  • 75 Hamzeh-Cognasse H, Mansour A, Reizine F, Mismetti P, Gouin-Thibault I, Cognasse F. Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection. Virol J 2021; 18 (01) 211
    CrossrefPubMedGoogle Scholar
  • 76 Vassiliou AG, Keskinidou C, Jahaj E. et al. ICU admission levels of endothelial biomarkers as predictors of mortality in critically ill COVID-19 patients. Cells 2021; 10 (01) 186
    CrossrefPubMedGoogle Scholar
  • 77 Watany MM, Abdou S, Elkolaly R, Elgharbawy N, Hodeib H. Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clin Exp Med 2022; 22 (04) 567-575
    CrossrefPubMedGoogle Scholar
  • 78 Lipcsey M, Persson B, Eriksson O. et al. The outcome of critically ill COVID-19 patients is linked to thromboinflammation dominated by the kallikrein/kinin system. Front Immunol 2021; 12: 627579
    CrossrefPubMedGoogle Scholar
  • 79 Sinkovits G, Réti M, Müller V. et al. Associations between the von Willebrand factor-ADAMTS13 axis, complement activation, and COVID-19 severity and mortality. Thromb Haemost 2022; 122 (02) 240-256
    Article in Thieme ConnectPubMedGoogle Scholar
  • 80 Kreutz R, Algharably EAE, Azizi M. et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020; 116 (10) 1688-1699
    CrossrefPubMedGoogle Scholar
  • 81 Pucci F, Annoni F, Dos Santos RAS, Taccone FS, Rooman M. Quantifying renin-angiotensin-system alterations in COVID-19. Cells 2021; 10 (10) 2755
    CrossrefPubMedGoogle Scholar
  • 82 Cabrera LE, Pekkarinen PT, Alander M. et al. Characterization of low-density granulocytes in COVID-19. PLoS Pathog 2021; 17 (07) e1009721
    CrossrefPubMedGoogle Scholar
  • 83 Denny MF, Yalavarthi S, Zhao W. et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010; 184 (06) 3284-3297
    CrossrefPubMedGoogle Scholar
  • 84 Veras FP, Pontelli MC, Silva CM. et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 2020; 217 (12) e20201129
    CrossrefPubMedGoogle Scholar
  • 85 Zuo Y, Yalavarthi S, Shi H. et al. Neutrophil extracellular traps in COVID-19. JCI Insight 2020; 5 (11) e138999
    PubMedGoogle Scholar
  • 86 Englert H, Rangaswamy C, Deppermann C. et al. Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine 2021; 67: 103382
    CrossrefPubMedGoogle Scholar
  • 87 Middleton EA, He XY, Denorme F. et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020; 136 (10) 1169-1179
    CrossrefPubMedGoogle Scholar
  • 88 Ng H, Havervall S, Rosell A. et al. Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID-19. Arterioscler Thromb Vasc Biol 2021; 41 (02) 988-994
    CrossrefPubMedGoogle Scholar
  • 89 Skendros P, Mitsios A, Chrysanthopoulou A. et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 2020; 130 (11) 6151-6157
    CrossrefPubMedGoogle Scholar
  • 90 Manfredi AA, Rovere-Querini P, D'Angelo A, Maugeri N. Low molecular weight heparins prevent the induction of autophagy of activated neutrophils and the formation of neutrophil extracellular traps. Pharmacol Res 2017; 123: 146-156
    CrossrefPubMedGoogle Scholar
  • 91 Sidiropoulos K, Viteri G, Sevilla C. et al. Reactome enhanced pathway visualization. Bioinformatics 2017; 33 (21) 3461-3467
    CrossrefPubMedGoogle Scholar